Agenus Inc's Form 4/A amendment
AmendedMiNK Therapeutics, Inc. (INKT) · filed May 26, 2023
- Accession no.
- 0000950170-23-024567
- Filed
- May 26, 2023
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 5, 2023
This filing lists no transactions. It carries over 4 transactions from the original filing that it did not restate. Open-market purchases total $260.4K.
This amendment restates part of 0000950170-23-018401 (filed May 5, 2023). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Agenus IncCIK 0001098972 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000950170-23-018401 (filed May 5, 2023).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2023 | Common Stock | PPurchaseAcquired | +128,689 | $1.08F1,F2 | +$138,984.12 | 21,473,374 | Direct | |
| May 4, 2023 | Common Stock | PPurchaseAcquired | +21,473 | $1.22F2,F3 | +$26,197.06 | 21,494,847 | Direct | |
| May 5, 2023 | Common Stock | PPurchaseAcquired | +100,000 | $0.95 | +$95,000 | 21,594,847 | Direct | |
| May 5, 2023 | Common Stock | PPurchaseAcquired | +200 | $1.25 | +$250 | 21,595,047 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
Referenced by the price of 1 transaction in Table I.
- F2
Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
- F3
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 5, 2023, Agenus Inc. ("Agenus") disclosed a transaction involving 100,000 Mink Therapeutics shares. It agreed to purchase such shares from Garo Armen, the CEO and Chairman of Agenus, at Dr. Armen's original purchase price, which was lower than the market price at the time of the proposed purchase. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the Mink Therapeutics shares were returned to Dr. Armen, and the purchase price was given back to Agenus. This amendment accounts for the changes in Agenus' ownership following the reversal of this transaction.